NIH R01 · 2024
A precision therapy approach to red cell transfusion for sickle cell disease
ABSTRACT Red blood cell transfusion remains a life-saving therapy for patients with sickle cell disease (SCD). A major problem is the high rate of alloimmunization (antibody formation against transfused red cells) that occurs in transfused patients with SCD. Alloimmunization leads to delays in care, increases costs, and makes transfusion therapy unsafe and impossible for some patients. The most common antibodies formed by patients with SCD are directed against the Rh blood group system. Studies performed by our group and others demonstrate RH genetic variants in patients with SCD and Black donors is a major risk factor leading to the high incidence of Rh alloimmunization, and the complexity…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.